STAAR Surgical Company (STAA) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
19 Dec, 2025Executive summary
Special Meeting of Stockholders adjourned to January 6, 2026, at Alcon's request under the merger agreement.
The record date for voting eligibility remains October 24, 2025.
The proposed transaction involves a merger agreement between STAAR and Alcon.
Stockholders are encouraged to review all SEC filings related to the transaction.
Voting matters and shareholder proposals
Stockholders will vote on the proposed merger with Alcon at the rescheduled Special Meeting.
Proxy materials, including the definitive proxy statement, have been distributed and supplemented.
Board of directors and corporate governance
Directors, executive officers, and certain employees may be considered participants in the proxy solicitation.
Information on directors and executive officers, including their stock ownership, is available in the proxy statement and annual filings.
Latest events from STAAR Surgical Company
- Leadership changes, strategic reset, and key governance votes define the 2026 proxy.STAA
Proxy filing4 May 2026 - Virtual annual meeting to vote on directors, equity plan, auditor, and executive pay.STAA
Proxy filing4 May 2026 - Q4 sales rose 18% year-over-year on China recovery; 2026 outlook remains positive.STAA
Q4 20254 Mar 2026 - Financial headwinds ease as global expansion and cost controls set stage for growth rebound.STAA
45th Annual William Blair Growth Stock Conference3 Feb 2026 - Record Q2 sales and margin gains drove a raised FY2024 outlook and global ICL growth.STAA
Q2 20242 Feb 2026 - Record Q2, raised outlook, and global market share gains highlight strong momentum.STAA
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Strong Q1 growth, robust cash flow, and expansion in China and the U.S. set stage for continued market share gains.STAA
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Q3 net income doubled on 10% sales growth, with guidance and liquidity reaffirmed.STAA
Q3 202417 Jan 2026 - EVO lens gains share globally, with strong growth in Japan and stabilization in China.STAA
Stephens 26th Annual Investment Conference | NASH202413 Jan 2026